Jinhe Biotechnology CO., LTD. (SHE:002688)
China · Delayed Price · Currency is CNY 4.850
-0.120 (-2.41%)
Jun 11, 2026, 1:55 PM CST
SHE:002688 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,977 | 2,860 | 2,366 | 2,168 | 2,117 | 2,072 |
Other Revenue | 18.09 | 18.09 | 4.99 | 6.04 | 5.82 | 5.8 |
| 2,995 | 2,878 | 2,371 | 2,174 | 2,123 | 2,078 | |
Revenue Growth (YoY) | 20.94% | 21.41% | 9.04% | 2.42% | 2.15% | 14.51% |
Cost of Revenue | 2,020 | 1,944 | 1,641 | 1,572 | 1,545 | 1,472 |
Gross Profit | 975.22 | 934.59 | 729.97 | 602.51 | 577.47 | 605.66 |
Selling, General & Admin | 519.41 | 502.09 | 401.98 | 367.95 | 352.78 | 316.37 |
Research & Development | 113.39 | 116.55 | 94 | 74 | 82.28 | 72.25 |
Other Operating Expenses | 13.45 | 13.3 | 8.14 | 5.82 | 7.75 | 12.15 |
Operating Expenses | 651.45 | 635.51 | 518.11 | 454.08 | 444.34 | 402.65 |
Operating Income | 323.78 | 299.09 | 211.85 | 148.43 | 133.13 | 203.01 |
Interest Expense | -88.15 | -89.94 | -80.34 | -60.03 | -36.41 | -52.34 |
Interest & Investment Income | 8.01 | 8.16 | 6.9 | 8.37 | 1.9 | 1.72 |
Currency Exchange Gain (Loss) | -8.78 | -8.78 | 8.92 | 8.85 | 40.34 | -8.83 |
Other Non Operating Income (Expenses) | -10.77 | -3.55 | -28.48 | -7.33 | -15.79 | -4.87 |
EBT Excluding Unusual Items | 224.08 | 204.97 | 118.85 | 98.29 | 123.18 | 138.68 |
Impairment of Goodwill | -174.99 | -174.99 | -39.77 | -5.62 | -7.74 | -11.04 |
Gain (Loss) on Sale of Investments | -2.53 | -2.4 | -1.22 | -1.52 | -3.94 | - |
Gain (Loss) on Sale of Assets | -2.67 | -2.66 | 0.19 | -0.36 | -0.25 | 4.87 |
Asset Writedown | -5.52 | -3.82 | -1.11 | -0.93 | -0.46 | -1.28 |
Other Unusual Items | 18.15 | 18.05 | 20.83 | 11.65 | 8.05 | 11.69 |
Pretax Income | 56.52 | 39.15 | 97.78 | 101.5 | 118.84 | 142.91 |
Income Tax Expense | 55.94 | 50.13 | 13.46 | 7.06 | 0.73 | 20.82 |
Earnings From Continuing Operations | 0.57 | -10.98 | 84.32 | 94.43 | 118.11 | 122.09 |
Minority Interest in Earnings | 38.16 | 38.54 | 15.88 | -7.98 | -42.5 | -28.1 |
Net Income | 38.74 | 27.56 | 100.2 | 86.46 | 75.62 | 93.99 |
Net Income to Common | 38.74 | 27.56 | 100.2 | 86.46 | 75.62 | 93.99 |
Net Income Growth | -63.52% | -72.50% | 15.90% | 14.34% | -19.55% | -19.89% |
Shares Outstanding (Basic) | 780 | 781 | 774 | 780 | 780 | 696 |
Shares Outstanding (Diluted) | 780 | 781 | 774 | 780 | 780 | 696 |
Shares Change (YoY) | 1.00% | 0.81% | -0.76% | -0.01% | 12.16% | 6.74% |
EPS (Basic) | 0.05 | 0.04 | 0.13 | 0.11 | 0.10 | 0.14 |
EPS (Diluted) | 0.05 | 0.04 | 0.13 | 0.11 | 0.10 | 0.14 |
EPS Growth | -63.88% | -72.72% | 16.79% | 14.34% | -28.27% | -24.94% |
Free Cash Flow | 94.05 | 148.64 | 136.18 | -258.45 | -277.69 | -230.74 |
Free Cash Flow Per Share | 0.12 | 0.19 | 0.18 | -0.33 | -0.36 | -0.33 |
Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.100 | 0.100 | - |
Gross Margin | 32.56% | 32.47% | 30.79% | 27.71% | 27.20% | 29.15% |
Operating Margin | 10.81% | 10.39% | 8.94% | 6.83% | 6.27% | 9.77% |
Profit Margin | 1.29% | 0.96% | 4.23% | 3.98% | 3.56% | 4.52% |
Free Cash Flow Margin | 3.14% | 5.17% | 5.75% | -11.89% | -13.08% | -11.10% |
EBITDA | 564.48 | 528.74 | 397.33 | 321.3 | 282.31 | 333.98 |
EBITDA Margin | 18.85% | 18.37% | 16.76% | 14.78% | 13.30% | 16.07% |
D&A For EBITDA | 240.71 | 229.66 | 185.47 | 172.86 | 149.18 | 130.97 |
EBIT | 323.78 | 299.09 | 211.85 | 148.43 | 133.13 | 203.01 |
EBIT Margin | 10.81% | 10.39% | 8.94% | 6.83% | 6.27% | 9.77% |
Effective Tax Rate | 98.99% | 128.06% | 13.77% | 6.96% | 0.61% | 14.57% |
Revenue as Reported | 2,995 | 2,878 | 2,371 | 2,174 | 2,123 | 2,078 |
Advertising Expenses | - | 34.64 | 27.74 | 20.64 | 12.16 | 5.36 |